Pharmaceuticals, Biotechnology and Life Sciences
Proteostasis Therapeutics has started with the phase 2 study of cystic fibrosis treatment by dosing the first patient, after a successful Phase 1 test of PTI’s combinations.
BioCity, and Oxford AHSN are launching a new Accelerator Programme in Berkshire and South Oxfordshire to catalyse growth in Thames Valley’s world-class health and life sciences cluster by supporting the development of start-ups, spin-outs and growth companies across the region’s research, clinical and commercial base.
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 23, 2019 the Compensation Committee of…
Inovio Pharmaceuticals published its positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus…
LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today…
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first…
DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology…
ImaginAb has started the clinical trial of its lead product, CD8 tracer Zr-Df-IAB22M2C, a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells.
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 7,142,858 shares of…
Immix Biopharma, said Tuesday it got a letter from the FDA authorizing it to expand its phase 1b/2a clinical trial of…